Growth Hormone Research
SLU-PP-332 (5mg)
SKU: SUP-006-5MG
Out of Stock
$105.99
Notify me when back in stock
SLU-PP-332 — Pan-ERR Agonist Studied as a Research Exercise Mimetic
SLU-PP-332 (5mg) is supplied in Australia by Aussie Peptides with fast domestic shipping to all states and territories.
SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors — ERRα, ERRβ, and ERRγ — a family of orphan nuclear receptors that act as master regulators of mitochondrial biogenesis, oxidative phosphorylation, and skeletal-muscle oxidative capacity. Despite the name, the ERRs do not bind oestrogen; they share sequence homology with the estrogen receptor but use endogenous co-activators and metabolic signalling rather than steroid ligands.
The compound was developed by researchers at Saint Louis University and has been characterised in published preclinical work as a research tool to probe ERR-driven metabolic adaptations. In rodent studies, administration has been associated with increased mitochondrial content in skeletal muscle, increased running endurance, and improvements in metabolic markers in diet-induced obese models — patterns of adaptation that overlap with those induced by aerobic exercise. For this reason, SLU-PP-332 is often discussed in the literature as a research "exercise mimetic", though that label refers to the molecular pathways activated rather than to any clinical use.
Key Research Areas for SLU-PP-332
- ERR Pathway Research — Pan-agonist used as a pharmacological tool to study ERRα/β/γ activation in metabolically active tissues
- Mitochondrial Biogenesis — Studied in preclinical models for effects on mitochondrial content and oxidative capacity in skeletal muscle
- Endurance Adaptation Research — Investigated in rodent treadmill models for changes in time-to-exhaustion and substrate utilisation
- Metabolic Inflammation Research — Examined in diet-induced obese mouse models for body-composition and metabolic-marker endpoints
- Exercise-Mimetic Mechanism Research — Used to dissect which transcriptional adaptations to exercise can be reproduced via direct receptor activation
Supplied as high-purity powder. 5mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.
⚠ For in-vitro research and laboratory use only. Not for human consumption.
Product Specifications
| Compound | SLU-PP-332 (5mg) |
| Category | Growth Hormone Research |
| Purity | ≥ 99% (HPLC & Mass Spec Verified) |
| Form | Lyophilised Powder |
| Storage (Lyophilised) | -20 °C — protect from light & moisture |
| Storage (Reconstituted) | 2–8 °C — use within 8–12 weeks |
| Reconstitution | Bacteriostatic water (recommended) |
⚠ For in-vitro research and laboratory use only. Not intended for human or veterinary use. By purchasing, you confirm you are a qualified researcher and will use this compound in accordance with all applicable laws and regulations.
Frequently Bought Together
Frequently Asked Questions
What is SLU-PP-332?
SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors — ERRα, ERRβ, and ERRγ. These are nuclear receptors that act as master regulators of mitochondrial biogenesis and oxidative metabolism. Despite the name, ERRs are not activated by oestrogen — they share sequence homology with the estrogen receptor but signal through different mechanisms involving metabolic co-activators.
Why is SLU-PP-332 called an 'exercise mimetic'?
Because in published rodent studies, administering SLU-PP-332 produces patterns of cellular adaptation that overlap with those induced by aerobic exercise — increased mitochondrial content in skeletal muscle, increased oxidative capacity, increased treadmill endurance, and improvements in metabolic markers in diet-induced obese models. The 'exercise mimetic' label refers to the molecular pathways activated, not to any clinical use or claim that it replaces exercise.
What does the published research show?
SLU-PP-332 was developed and characterised by researchers at Saint Louis University. Published preclinical work has reported increased running endurance in mice, increased mitochondrial content in skeletal muscle, and improvements in body-composition and metabolic-marker endpoints in diet-induced obese mouse models. There are no published human clinical trials at the time of writing — it remains an investigational research compound.
How is SLU-PP-332 different from MOTS-c or NAD+?
All three relate to mitochondrial biology but act at different points. MOTS-c is a mitochondrially-derived peptide that signals to the nucleus to influence metabolic gene expression. NAD+ is a coenzyme directly consumed by mitochondrial energy-production reactions. SLU-PP-332 acts upstream by activating the ERR transcription factors that drive mitochondrial biogenesis itself — increasing the number and capacity of mitochondria rather than supplying substrate or signalling molecules.
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a small molecule — a synthetic ERR agonist — not a peptide. It is supplied as powder for research-protocol preparation rather than as a lyophilised vial for reconstitution and injection.
How should SLU-PP-332 be stored?
Store the powder at room temperature in a cool, dry place away from light and moisture. For longest shelf life, refrigeration is recommended. Reseal tightly between uses.
Where to buy SLU-PP-332 in Australia?
SLU-PP-332 (5mg) is available through Aussie Peptides with fast domestic shipping to all Australian states and territories. Every vial is dispatched from within Australia — no customs delays. Each batch undergoes third-party analysis and the Certificate of Analysis is available to view in our CoA Library.
What is the availability and cost of SLU-PP-332?
SLU-PP-332 (5mg) is currently out of stock at Aussie Peptides. SLU-PP-332 (5mg) is priced at $105.99 per vial at Aussie Peptides. All orders ship domestically within Australia, and batch CoAs are available in our CoA library.